Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.
You may also be interested in...
Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.
Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.
As Pfizer Faces Brand Drug Challenges, Management Pushes Cost Cuts
Executives head off questions about dramatic transformational changes during third quarter earnings call; Fablyn is delayed three months by FDA.